News
Matwings Technology and Revvity Announce Strategic Partnership to Build an AI for Science Innovation Ecosystem
Oct 30, 2026

On October 29, Shanghai Matwings Technology Co., Ltd. and Revvity officially signed a strategic cooperation agreement to deepen innovation collaboration in AI for Science. By combining AI algorithms with advanced laboratory automation technologies, the partnership aims to accelerate scientific discovery and the translation of research breakthroughs into real-world applications across the life sciences.

Hong Liang, Founder and Chief Scientist of Matwings Technology, and Liu Jiang, Vice President and General Manager of Greater China at Revvity, signed the agreement on behalf of their respective companies. The signing ceremony was also attended by Li Mingchen, Chief Technical Scientist of Matwings Technology AI Lab; Luo Kuan, Director of Government Affairs and Head of the Autonomous Laboratory at Matwings Technology; Zheng Yin, Marketing Director of Greater China at Revvity; and Li Yuhu, Head of the Life Sciences Market Development Team at Revvity.

Figure 1: Strategic Partnership Signing Ceremony Between Matwings Technology and Revvity

Artificial intelligence is reshaping life sciences research. However, realizing its full potential depends heavily on efficient experimental validation, automated laboratory platforms, and digital research infrastructure. Bridging the gap between computational prediction and experimental validation to establish a continuously evolving R&D feedback loop is essential to scaling AI for Science applications.

Matwings Technology leverages AI to advance protein research and development, providing end-to-end AI solutions for biopharmaceuticals, biomanufacturing, and related fields. Powered by MatwingsVenus®, its integrated computational and experimental protein R&D platform, the company connects AI-driven molecular design with automated experimental validation, accelerating the translation of scientific innovations into industrial applications.

With more than three decades of experience, Revvity has deployed over 600 automated systems worldwide [1]. Its automation capabilities have expanded beyond high-throughput screening to advanced research areas such as genomics, organoids, and synthetic biology, providing a strong foundation for transforming traditional linear R&D processes into efficient, closed-loop workflows.

Building on Matwings Technology's expertise in AI foundation models, protein design, and biological computing, together with Revvity's extensive experience in laboratory automation and life sciences solutions, as well as its localized R&D and manufacturing resources in Taicang, the two companies will focus on key applications in drug discovery and development, protein engineering, and biomanufacturing. Together, they will explore next-generation Lab-in-the-Loop R&D models and develop integrated, end-to-end solutions combining AI algorithms, advanced scientific instrumentation, and laboratory services.

 

Hong Liang

Founder and Chief Scientist, Matwings Technology

"AI is rapidly transforming how life sciences research is conducted. This partnership will further integrate artificial intelligence with experimental science and drive continuous improvements in research workflows.

As a trusted global enabler and long-term partner in innovative drug development, Revvity supports the entire value chain, from target discovery to industrial application. We look forward to combining our respective strengths to explore new approaches to AI-driven scientific discovery and create new opportunities for innovation across the biopharmaceutical and life sciences industries."

 

Liu Jiang

Vice President and General Manager, Greater China, Revvity

"The value of AI extends beyond the models themselves. It also lies in the efficiency of experimental validation and continuous iteration.

Revvity has long focused on integrating scientific instruments, reagents, and automated workflows, while Matwings Technology brings strong capabilities in AI foundation models, protein design, and biological computing.

Through this partnership, we aim to deepen the integration of experimental science and artificial intelligence, establish a new paradigm for AI for Science, accelerate the translation of scientific innovations into practical applications, and drive further progress in the life sciences industry."